FDA Approves KERENDIA — SUPPL Submission by BAYER HLTHCARE, Not disclosed in the FDA record.

Key facts

Regulatory context

This application was reviewed under FDA's SUPPL submission pathway. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What was approved

FDA's record shows BAYER HLTHCARE as the sponsor of KERENDIA, with the generic name recorded as unspecified and dosage form TABLET. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. This specific application is submission type SUPPL (submission number 11) under application number NDA215341, with a submission status date of 20260916. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

BAYER HLTHCARE’s FDA history

Argus HQ has recorded 1 total FDA action tied to BAYER HLTHCARE: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

Frequently asked questions

What review priority did FDA assign?

FDA designated this submission as: PRIORITY.

What dosage form is KERENDIA?

KERENDIA is formulated as: TABLET.

What did FDA approve?

FDA's record shows nda approval for KERENDIA (unspecified), dosage form TABLET, sponsored by BAYER HLTHCARE, under application number NDA215341. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What does the submission type mean?

A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information.

Related enforcement actions

• Approval (recent): INTRABIO — NDA approval: AQNEURSA (unspecified) →
• Approval (recent): AUROBINDO PHARMA LTD — ANDA approval: CYCLOSPORINE (unspecified) →
• Approval (recent): CIPLA — ANDA approval: CALCIUM GLUCONATE IN SODIUM CHLORIDE (unspecified) →
• Approval (recent): ZYDUS LIFESCIENCES — ANDA approval: TRETINOIN (unspecified) →
• Approval (recent): CURIUM — NDA approval: BEXLUTRY (unspecified) →
• Approval (recent): STRIDES PHARMA — ANDA approval: MILNACIPRAN HYDROCHLORIDE (unspecified) →
• Approval (recent): MACLEODS PHARMS — ANDA approval: MILNACIPRAN HYDROCHLORIDE (unspecified) →
• Approval (recent): EMERGE BIOSCIENCE PTE. LTD. — BLA approval: GARZULYS (unspecified) →